22 December 2016
EFPIA Japan

Ole Mølskov Bech to become new chairman of EFPIA JapanTOKYO—22 December 2016— EFPIA Japan announced today that Ole Mølskov Bech(President and Representative Director, Novo Nordisk Japan Ltd.) has been appointed thenew chairman of EFPIA Japan, effective 1 January 2017.
Philippe Fauchet (President and Representative Director, GlaxoSmithKline K.K.), who
continues in his current position as vice chairman, and David Fredrickson (President andRepresentative Director, AstraZeneca K.K.), who has been newly appointed vicechairman, will support Ole Mølskov Bech in his new role.
“EFPIA Japan has been focused during the past couple of years on ensuring patient
access to innovative medicines in a sustainable Japanese healthcare system”, said Ole
Mølskov Bech. “These objectives become even more of an imperative given thequestions being raised about the pricing and access system today in Japan. As chairmanof EFPIA Japan, I hope to be able to partner with key stakeholders in Japan fortransparent and real dialogue and to ensure that EFPIA Japan is ready to contributeconstructive propositions to the discussion.”
EFPIA Japan Board Members as of 1 January 2017
ChairmanOle Mølskov Bech (Novo Nordisk Pharma Ltd.)
Vice Chairmen
Philippe Fauchet (GlaxoSmithKline K.K.)
David Fredrickson (AstraZeneca K.K.)
Directors
Dirk Kosche (Novartis Pharma K.K.)
Thorsten Poehl (Nippon Boehringer Ingelheim Co., Ltd.
Jacques Nathan (Sanofi K.K.)
Heike Prinz (Bayer Yakuhin, Ltd.)
Leo Lee (Merck Serono Co., Ltd.)
Stefan Sakurai (LEO Pharma K.K.)
Director
Simon Collier (EFPIA Japan)
GeneralNewNewNew###__________________________________________________________________EFPIA Japan Office
Marunouchi Kitaguchi Bldg., 6-5, Marunouchi 1-chome, Chiyoda-ku, Tokyo 100-8265
Tel: +81-3-6301-3066 Fax: +81-3-6301-3060

About EFPIA Japan:
Established in 2002, EFPIA Japan represents 24 R&D-based European pharmaceuticalcompanies operating in Japan. In 2015, combined sales from the member companies
accounted for roughly 24% of the pharmaceutical market in Japan. The mission of EFPIA
Japan is to “Contribute to healthcare and patients in Japan through the early introductionof innovative medicines and vaccines”. EFPIA Japan aims to strengthen dialogue withdecision-makers in order to improve Japanese healthcare for all.
About EFPIA (European Federation of Pharmaceutical Industries and Associations):
EFPIA, EFPIA Japan’s partner organisation, is headquartered in Brussels and represents
the pharmaceutical industry operating in Europe. Through its direct membership of 33
national associations and 42 leading pharmaceutical companies, EFPIA provides thevoice of 1,900 companies committed to researching, developing and bringing new
medicines to improve health and quality of life around the world.
For more information please visit:
http://www.efpia.eu (EFPIA)
http://efpia.jp/English/index-e.html (EFPIA Japan)

Contact:
Naoko Miyoshi, Chair of EFPIA Japan Public Relations Committee
Bayer Yakuhin, Ltd.
TEL: 06-6133-7333
Mail: naoko.miyoshi@bayer.com

2Dr. Ole Mølskov Bech’s Curriculum Vitae
Birth Place

Denmark

Birth Year

1959

Current Position
President and Representative Director, Novo Nordisk Pharma Ltd.
Education
1986

Medical Degree, University of Copenhagen2002

MBA from Scandinavian International Management InstituteWork Experience
1986-1990

Research Fellow, Institute of Pharmacology, University of Aarhus andClinical Training at Gentofte County Hospital

Dec 1990

Joined Novo Nordisk A/S as International Product Manager and based inDenmarkJun 1992

Regional Manager, International Operations, Region VFeb 1995

Director and Executive Assistant for COO

April 1997

Director, Marketing Support, International Operations Marketing

Dec 1998

Vice President, Customer Service and ShippingSep 2000

Vice President, Product Supply Operations

Aug 2001

Vice President, DAWN Project, Operations

Oct 2002

Medical, Marketing and Business Development Director
Regional Office Far East, International Operations – Based in Singapore

Nov 2003

Medical Director, International Operations Clinical Development Centre
Responsible for clinical development activities in Asia,Latin America, Africa, Middle East, Eastern Europe and Russia – Based inSingaporeFeb 2006

Vice President, International Operations Clinical Development Centre,
Based in Beijing, China
Member of IO Management and Global Development Management

Jan 2011

Corporate Vice President, International Operations Clinical, Medical &Regulatory – Based in Zurich, Switzerland（As of December, 2016 ）Member of IO Management and Global Development Management
Aug 2012

Corporate Vice President, Business Area Near East,
International Operations – Based in Istanbul,Turkey
Responsible for business activities in 11 countries in the Near East
Member of IO Management

Jan 2016

Senior Vice President, Region Japan & Korea, International Operations,President and Representative Director of Novo Nordisk Pharma Ltd.
Responsible for business activities in Japan and Korea– Based inTokyo, Japan
Member of Novo Nordisk Management Board

External Activities
2003-2006

Committee Member, Danish Business Association of Singapore, Singapore

2006-2012

Board Member, Danish Chamber of Commerce in China, Beijing, China

2007-2011

Board of Trustee, International School of Beijing, Beijing, China

Jul 2016

Vice Chairman, European Federation of Pharmaceutical Industries(EFPIA Japan)

Jan 2017

Chairman, European Federation of Pharmaceutical Industries(EFPIA Japan)

OthersDr. Bech has published more than 30 papers and abstracts and has held lectures inEurope, Asia, the Middle East and Latin America.